| Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth |
2021-09-16 |
| Anjarium Biosciences–Citadel: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Surveyor Capital |
2021-09-16 |
| Anjarium Biosciences–Huntsworth: public relations, 202109 service existent by Medistrava Consulting |
2021-09-16 |
| Anjarium Biosciences–Omega Funds: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Omega Funds |
2021-09-16 |
| Anjarium Biosciences–Pfizer: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Pfizer Ventures |
2021-09-16 |
| Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv |
2021-09-16 |
| Touchlight–Bridford Group: investment, 202109 financing round extension £50m incl co-lead investor Bridford Investments Ltd |
2021-09-15 |
| Touchlight–Novator Partners: investment, 202109 financing round extension £50m incl co-lead investor Novator Partners |
2021-09-15 |
| Touchlight–SEVERAL: investment, 202109 financing round extension £50m bringing total round to £92m led by Bridford + Novator |
2021-09-15 |
| TreeFrog Therapeutics–SEVERAL: investment, 202109 financing round Series B $75m (€64m) led by Bpifrance Large Venture |
2021-09-13 |
| Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets |
2021-09-09 |
| TIB Molbiol–Roche: investment, 202109– acquisition 100% of TIB Mobiol Group by Roche SIGNED |
2021-09-09 |
| EnteroBiotix–Scius Communications: public relations, 202109 supply service existent by Scius Communications |
2021-09-07 |
| EnteroBiotix–SEVERAL: investment, 202109 financing round Series A £15.5m ($21.5m) led by Thairm Bio |
2021-09-07 |
| Owlstone–Horizons Ventures: investment, 202109 financing round Series D totalling $58m incl existing + lead investor Horizons Ventures |
2021-09-07 |
| Owlstone–SEVERAL: investment, 202109 financing round Series D $58m of Owlstone Medical led by existing investor Horizons Ventures |
2021-09-07 |
| Ascendis Pharma–SEVERAL: investment, 202108– public offering $400m + up to $60m of ADSs |
2021-08-31 |
| Tissium–Cathay Capital: investment, 202108 financing round Series C totalling €50m incl new + co-lead investor Cathay Health |
2021-08-31 |
| Tissium–SEVERAL: investment, 202108 financing round Series C €50m co-led by Cathay Health + Sofinnova Partners |
2021-08-31 |
| Tissium–Sofinnova: investment, 202108 financing round Series C totalling €50m incl existing + co-lead investor Sofinnova Partners |
2021-08-31 |
| Laronde–Flagship Pioneering: investment, 202108 financing round Series B totalling $440m incl founding investor Flagship Pioneering |
2021-08-30 |
| Laronde–SEVERAL: investment, 202108 financing round Series B $440m with founding investor Flagship Pioneering |
2021-08-30 |
| Lynk Pharmaceuticals–SEVERAL: investment, 202108 financing round $50m led by Lilly Asia Ventures |
2021-08-27 |
| HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami |
2021-08-26 |
| Cardior Pharmaceuticals–BMS: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BMS |
2021-08-25 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 202108 financing round Series B totalling €64m incl existing + co-investor HTGF |
2021-08-25 |
| Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital |
2021-08-25 |
| DiCE Molecules–1AB Media: public relations, 202108 service existent by 1AB Media |
2021-08-24 |
| DiCE Molecules–RA Capital: investment, 202108 financing round Series C-1 totalling $60m incl co-lead investor RA Capital Management |
2021-08-24 |
| DiCE Molecules–Sands Capital: investment, 202108 financing round Series C-1 totalling $60m incl co-lead investor Sands Capital |
2021-08-24 |
| DiCE Molecules–SEVERAL: investment, 202108 financing round Series C-1 $60m co-led by RA Capital + Sands Capital |
2021-08-24 |
| Jnana Therapeutics–SEVERAL: investment, 202108 financing round Series B $50m led by RA Capital + incl all exising investors |
2021-08-18 |
| Ranok Therapeutics–SEVERAL: investment, 202108 financing round Series B $40m co-led by Lapam Capital + Shanghai Healthcare Capital |
2021-08-18 |
| Vigil Neuroscience–SEVERAL: investment, 202108 financing round Series B $90m led by new investor Vida Ventures |
2021-08-18 |
| Beckley Psytech–Adage Capital: investment, 202108 financing round Series B totalling $80m incl co-investor Adage Capital Management LP |
2021-08-16 |
| Beckley Psytech–Bicycle Day Ventures: investment, 202108 financing round Series B totalling $80m incl existing + co-investor Bicycle Day Ventures |
2021-08-16 |
| Beckley Psytech–Delphi VC: investment, 202108 financing round Series B totalling $80m incl co-investor Delphi VC |
2021-08-16 |
| Beckley Psytech–FTI Consulting: public relations, 202108 service existent by FTI Consulting |
2021-08-16 |
| Beckley Psytech–Integrated VC: investment, 202108 financing round Series B totalling $80m incl lead investor Integrated |
2021-08-16 |
| Beckley Psytech–Leafy Tunnel: investment, 202108 financing round Series B totalling $80m incl co-investor Leafy Tunnel |
2021-08-16 |
| Beckley Psytech–LifeSci: public relations, 202108 service existent LifeSci Advisors is investor relations contact |
2021-08-16 |
| Beckley Psytech–Negev Capital: investment, 202108 financing round Series B totalling $80m incl co-investor Negev Capital |
2021-08-16 |
| Beckley Psytech–Palo Santo: investment, 202108 financing round Series B totalling $80m incl co-investor Palo Santo |
2021-08-16 |
| Beckley Psytech–Prime Movers Lab: investment, 202108 financing round Series B totalling $80m incl co-investor Prime Movers Lab |
2021-08-16 |
| Beckley Psytech–SEVERAL: investment, 202108 financing round Series B $80m (£58m) led by Integrated VC |
2021-08-16 |
| Ultromics–Alphabet: investment, 202108 financing round Series B totalling $33m incl new + co-investor GV |
2021-08-16 |
| Ultromics–BCBSA: investment, 202108 financing round Series B totalling $33m incl new + lead investor Blue Venture Fund |
2021-08-16 |
| Ultromics–SEVERAL: investment, 202108 financing round Series B $33m led by new investor Blue Venture Fund |
2021-08-16 |
| Ultromics–UnitedHealth: investment, 202108 financing round Series B totalling $33m incl new + co-investor Optum Ventures |
2021-08-16 |
| Ultromics–Univ Oxford: investment, 202108 financing round Series B totalling $33m incl existing + co-investor OSI |
2021-08-16 |
| Bayer–Berkeley Lights: plant research, 202108 collab multi-year €na RnD seeds and traits using Berkeley Lights Platform |
2021-08-11 |
| Visus Therapeutics–Life Sciences Partners: investment, 202108 financing round totalling $20m in preferred stock incl new + lead investor LSP |
2021-08-10 |
| Visus Therapeutics–SEVERAL: investment, 202108 financing round $20m in preferred stock led by new investor LSP |
2021-08-10 |
| OncXerna Therapeutics–Qiagen: molecular companion diagnostics, 202108– collab developm Xerna TME panel as NGS CDx for navicixizumab |
2021-08-09 |
| Qiagen–OncXerna Therapeutics: molecular companion diagnostics, 202108– license non-excl to Xerna TME panel as NGS CDx for Qiagen |
2021-08-09 |
| PepGen–LifeSci: public relations, 202108 service existent by LifeSci Communications |
2021-08-05 |
| PepGen–SEVERAL: investment, 202108 crossover financing round $112.5m with existing + new investors |
2021-08-05 |
| Vividion Therapeutics–Bayer: investment, 202108– acquisition $1.5b upfront + $500k milestones ANNOUNCED |
2021-08-05 |
| Sonoma Biotherapeutics–SEVERAL: investment, 202108 financing round Series B $265m led by Ally Bridge Group |
2021-08-04 |
| Circulomics–Pacific Biosciences: investment, 202108 acquisition €na of Circulomics by PacBio |
2021-08-03 |
| Engrail Therapeutics–Nan Fung: investment, 202108 financing round Series A extension totalling $32m inkl Alt- + Leadinvestor NFLS |
2021-08-03 |
| Engrail Therapeutics–SEVERAL: investment, 202108 financing round Series A extension $32m bringing total round to $64m led by NFLS |
2021-08-03 |
| Mestag Therapeutics–Alphabet: investment, 202108 seed financing round extension totalling $34m incl new + co-investor GV |
2021-08-03 |
| Mestag Therapeutics–Forbion: investment, 202108 seed financing round extension totalling $34m incl new + lead investor Forbion |
2021-08-03 |
| Mestag Therapeutics–JnJ: investment, 202108 seed financing round extension totalling $34m incl existing + co-investor JnJ Innovation JJDC Inc |
2021-08-03 |
| Mestag Therapeutics–Northpond Ventures: investment, 202108 seed financing round extension totalling $34m incl new + co-investor Northpond Ventures |
2021-08-03 |
| Mestag Therapeutics–SEVERAL: investment, 202108 seed financing round extension $34m led by Forbion bringing total seed round to $45m |
2021-08-03 |
| Mestag Therapeutics–SV Health Investors: investment, 202108 seed financing round extension totalling $34m incl existing + co-investor SVHI |
2021-08-03 |
| Translate Bio–Sanofi: investment, 202108– cash tender offer $3.2b at $38/share ANNOUNCED |
2021-08-03 |
| Evotec–SEVERAL: investment, 202108– proposed offering of ADSs via secondary US listing at Nasdaq Global Select Market FILED |
2021-08-02 |
| T-Knife–SEVERAL: investment, 202108 financing round Series B $110m led by new investor Fidelity Management and Research |
2021-08-02 |
| Topas Therapeutics–Epidarex Capital: investment, 202107 financing round Series B extension €18m incl existing investor Epidarex Capital |
2021-07-29 |
| Topas Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €18m bringing total round to €40m incl all existing investors |
2021-07-29 |
| Artios Pharma–Omega Funds: investment, 202107 financing round Series C totalling £110m ($153m) incl new + co-lead investor Omega Funds |
2021-07-27 |
| Artios Pharma–SEVERAL: investment, 202107 financing round Series C £110m ($153m) co-led by Omega Funds + TCG X |
2021-07-27 |
| Artios Pharma–TCG Crossover: investment, 202107 financing round Series C totalling £110m ($153m) incl new + co-lead investor TCG X |
2021-07-27 |
| Axa–SEVERAL: investment, 202107 raising of €1.9b equity by AXA IM Alts to invest in European Life Sciences primarly via Kadans Science Partner |
2021-07-26 |
| BioLegend–PerkinElmer: investment, 202107– acquisition $5.25b in cash + shares subject to certain adjustments ANNOUNCED |
2021-07-26 |
| Relief Therapeutics–SEVERAL: investment, 202107 private placement CHF15m with 71.4m common stock at CHF0.21/share to two US institutional investors |
2021-07-26 |
| Voluntis–Aptar: investment, 202106– cash tender offer €78.8m at €8.7/share announced with 64.6% committed by reference shareholders |
2021-07-23 |
| Slingshot Biosciences–Anterra Capital: investment, 202107 financing round Series A totalling $23m inc co-investor Anterra Capital |
2021-07-22 |
| Slingshot Biosciences–ARCH Venture: investment, 202107 financing round Series A totalling $23m inc co-investor ARCH Venture Partners |
2021-07-22 |
| Slingshot Biosciences–Northpond Ventures: investment, 202107 financing round Series A totalling $23m inc lead investor Northpond Ventures |
2021-07-22 |
| Slingshot Biosciences–SEVERAL: investment, 202107 financing round Series A $23m led by Northpond Ventures with ARCH Venture Partners + Anterra Capital |
2021-07-22 |
| Sophia Genetics–SEVERAL: investment, 202107 US IPO $234m+$35.1m with 13m+1.95m ordinary shares at $18/Share at Nasdaq Global Select Market |
2021-07-22 |
| Excellims–Covalent Bonds: public relations, 202107 service existent by Covalent Bonds |
2021-07-21 |
| 3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED |
2021-07-20 |
| Omniome–Pacific Biosciences: investment, 202107– acquisition $300m cash + $600m in shares + $200m milestones in cash + shares ANNOUNCED |
2021-07-20 |
| Pacific Biosciences–Casdin Capital: investment, 202107– private placement PIPE totalling $300m incl existing key investor Casdin Capital |
2021-07-20 |
| Pacific Biosciences–SEVERAL: investment, 202107– private placement PIPE $300m with 11.2m shares at $26.75/share to key existing investors |
2021-07-20 |
| Pacific Biosciences–SoftBank: investment, 202107– private placement PIPE totalling $300m incl existing key investor SoftBank |
2021-07-20 |
| Pacific Biosciences–T Rowe Price: investment, 202107– private placement PIPE totalling $300m incl existing key investor T Rowe Price Associates |
2021-07-20 |
| Intelligent Tissue Group–BioIVT: investment, 202107 acquisition €na of Tissue Solutions Ltd by BioIVT |
2021-07-19 |
| NanoSyrinx–Octopus Ventures: investment, 202107 seed financing round totalling £6.2m incl new + co-lead investor Octopus Ventures |
2021-07-19 |
| NanoSyrinx–SEVERAL: investment, 202107 seed financing round £6.2m co-led by Octopus Ventures + M Ventures |
2021-07-19 |
| NanoSyrinx–We are Pioneer Group: investment, 202107 seed financing round totalling £6.2m incl existing + co-investor WAPG |
2021-07-19 |
| Immunic–SEVERAL: investment, 202107 underwritten public offering $45m with 4.5m shares common stock at $10/share |
2021-07-14 |
| Kriya Therapeutics–SEVERAL: investment, 202107 financing round Series B $100m led by Patient Square Capital + incl new + existing investors |
2021-07-14 |
| Mobilion–SEVERAL: investment, 202107 financing round Series C $60m led by new investor D1 Capital Partners |
2021-07-13 |
| RayzeBio–48Hour Discovery: radiopharmaceuticals, 202107– strategic collab r+d of peptide-based radiopharmaceuticals |
2021-07-12 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
